TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03583931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS Decortication
Description: Surgical procedure to unroof all located collections of the pleural space through a chest wall incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinolytic Therapy
Description: Instillation of DNAse and tPA together through patient's chest tube already in placed to break down complex fluid collection in the pleural space. DNAse and tPA are are administered together only i.e. are not mutually exclusive.
Study: NCT01584804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Su-Huang antitussive capsule
Description: Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
Study: NCT02753608

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Collection of exhaled breath condensate
Description: An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
Study: NCT01285206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon polymer warming blanket
Description: Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
Study: NCT00358007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTV Reduction
Description: The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
Study: NCT02669459

Intervention type: DRUG
Group type: OTHER
Intervention: Imiquimod
Description: 12,5 mg imiquimod three times per week during 16 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ
Description: surgical treatment for CIN, current gold standard
Study: NCT04097366

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ABUS
Description: Automated whole breast ultrasound (ABUS) is undertaken with a large transducer panel placed on the breast in three positions. Resultant images are combined to make a 3D image of the breast.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CESM
Description: A high kV and a low kV image is taken in two standard views of each breast following the intravenous injection of an iodinated contrast agent.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ABB-MRI
Description: ABB-MRI is a shorter version of breast MRI. Standard T1W pre and post contrast images are acquired. A MIP and post-contrast T1 weighted image are read.
Study: NCT02316080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental bleaching
Description: Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Desensitizing therapy
Description: Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
Study: NCT00348985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT03491826

Intervention type: BIOLOGICAL
Intervention: rupture of membrane

Intervention type: BIOLOGICAL
Intervention: rupture of membrane
Study: NCT03214107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will be admitted at IRCM at 14:00. At 15:30, participants will performed a 60-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). During exercise, capillary glucose levels will be measured every 10 minutes. At 16:30, the exercise will be completed and capillary glucose levels will be monitored every 20 minutes for 1 hour. At 17:30, the participant will be discharged.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will be admitted at IRCM at 14:00. At 15:30, participants will performed a 60-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). During exercise, capillary glucose levels will be measured every 10 minutes. At 16:30, the exercise will be completed and capillary glucose levels will be monitored every 20 minutes for 1 hour. At 17:30, the participant will be discharged.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Snack
Description: Full snack or Distributed snack

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Snack
Description: Full snack or Distributed snack
Study: NCT01695135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (4 tablets) taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg tablet taken orally twice daily
Study: NCT02199366

Intervention type: PROCEDURE
Intervention: Cardiac magnetic resonance (cardiac MRI)
Description: Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
Study: NCT01488526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF treatment
Description: About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
Study: NCT03930693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Beetroot juice shot (70mL containing 400mg inorganic nitrate)
Study: NCT01010282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin and Polysorbate 80 based artificial tear
Description: 1-2 drops in each eye, as needed, but at least twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
Description: 1-2 drops in each eye, as needed, but at least twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
Description: 1-2 drops in each eye, as needed, but at least twice daily
Study: NCT03025724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan Kerastick
Description: Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue light source
Description: At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participant satisfaction survey
Description: Participants will be asked to fill out a satisfaction survey.
Study: NCT02385812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography Annual scan x3
Description: Annual scan x3

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography Baseline scan only
Description: Baseline scan only
Study: NCT03117387

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of the level of neuromuscular blockade
Description: Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of the level of neuromuscular blockade
Description: Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of the level of neuromuscular blockade
Description: Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of the level of neuromuscular blockade
Description: Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.
Study: NCT03424538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation
Description: 5-week-long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
Study: NCT02753608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of exhaled breath condensate
Description: An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
Study: NCT02006901

Intervention type: PROCEDURE
Intervention: microdecompression
Description: a minimal invasive surgical technique
Study: NCT00729937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: 4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: 4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
Study: NCT03930693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Beetroot juice shot (70mL containing 400mg inorganic nitrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Beetroot juice shot (70mL containing 400mg inorganic nitrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Beetroot juice shot (70mL containing 400mg inorganic nitrate)
Study: NCT02168907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study: NCT00555620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
Study: NCT02168907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00555620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study: NCT02562716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT00555620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
Study: NCT03276806

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tobacco dependence/smoking cessation counseling
Description: Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
Study: NCT02562716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Description: Undergo pancreatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Description: Undergo pancreatectomy
Study: NCT01522716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
Study: NCT03276806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tobacco dependence/smoking cessation counseling
Description: Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SDM
Description: SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LDCT brochure
Description: A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
Study: NCT00331799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
Study: NCT04579640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol
Study: NCT01775371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia (PCA)
Description: Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual opioid analgesia determined by the provider
Study: NCT00651339

Intervention type: DRUG
Intervention: botox
Description: botox injection
Study: NCT05054998

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI
Study: NCT02006901

Intervention type: PROCEDURE
Intervention: laminectomy
Description: The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
Study: NCT04257773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH Forgiveness Workbook Intervention
Description: Participants will be asked to complete the REACH Forgiveness Workbook

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH Forgiveness Workbook Intervention
Description: Participants will be asked to complete the REACH Forgiveness Workbook
Study: NCT03128931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric SedLine forehead EEG sensor
Description: Pediatric EEG sensor.
Study: NCT03252015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probe Drug Cocktail
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probe Drug Cocktail
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probe Drug Cocktail
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02192307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Potassium oxalate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium oxalate
Study: NCT01991600

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous sulphate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferric iron oxide-organic acid (Fe-OA)
Study: NCT00518531

Intervention type: DRUG
Group type: OTHER
Intervention: alendronate
Description: Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.

Intervention type: DRUG
Group type: OTHER
Intervention: alendronate
Description: Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.

Intervention type: DRUG
Group type: OTHER
Intervention: denosumab
Description: Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.

Intervention type: DRUG
Group type: OTHER
Intervention: denosumab
Description: Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
Study: NCT03073642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Education
Description: Together with hydrotherapy, patients will receive pain therapeutic education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Description: Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
Study: NCT03106740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline Hydrochloride 100mg Capsule
Description: Minocycline 100mg will be administered by mouth daily for 2 weeks

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-Positron Emission Tomography Imaging
Description: Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance-Positron Emission Tomography Imaging
Description: Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: 1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
Study: NCT00463385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
Study: NCT05054998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI